| Literature DB >> 32029982 |
U C Samudyatha1, Vipul Chaudhari1, Naresh Chauhan1, Rahul Damor1, J K Kosambiya1, Rikita Munshi1.
Abstract
CONTEXT: Clinical and epidemiological variables in the modified Faine's criteria offered low validity in our study setting. AIMS: Restructuring and validating modified Faine's criteria for leptospirosis to better suit health scenario of south Gujarat. SUBJECTS AND METHODS: Clinical, epidemiological, and laboratory features of derivation cohort (1216 suspected leptospirosis cases) admitted at a tertiary care hospital of south Gujarat (2007-2015) that significantly correlated with confirmed leptospirosis were used in binary logistic regression to derive scoring models and receiver operating characteristic to determine cutoff values. Validity and net reclassification improvement (NRI) were estimated in validation cohort (82 cases, 2016-2017) and algorithm for diagnosis was prepared.Entities:
Keywords: Microscopic agglutination test; modified Faine's criteria; net reclassification improvement; polymerase chain reaction
Year: 2020 PMID: 32029982 PMCID: PMC6985959 DOI: 10.4103/ijcm.IJCM_180_19
Source DB: PubMed Journal: Indian J Community Med ISSN: 0970-0218
Modified Faine’s criteria (2012) (scores) for the diagnosis of leptospirosis in cases of acute febrile illness
| Part A: Clinical data | Part B: Epidemiological factors | Part C: Bacteriological and laboratory findings |
|---|---|---|
| Headache (2) | Rainfall (5) | Isolation of leptospira in culture - diagnosis certain PCR (25) |
A score of 26 or more in parts A + B or a score 25 or more in parts A + B + C is considered diagnostic of leptospirosis. OR: Odds ratio, PCR: Polymerase chain reaction, IgM: Immunoglobulin M, MAT: Microscopic agglutination test, SAT: Slide agglutination test
Validity of different diagnostic criteria of leptospirosis (with Leptospirosis Burden Epidemiology Reference Group-2 criteria as reference standard)
| Criteria | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|---|---|---|---|---|
| Criteria that can be used at peripheral health centers | ||||
| Modified Faine’s criteria (parts A + B) | 5.0 | 88.0 | 25.0 | 57.0 |
| Rapid test (leptocheck) | 73.7 | 7.4 | 35.9 | 28.6 |
| Criteria that can be assessed at tertiary care hospital | ||||
| Modified Faine’s criteria (parts A + B + C) | 100.0 | 14.8 | 45.2 | 100.0 |
| IgM ELISA | 78.9 | 29.6 | 44.1 | 66.6 |
| MAT | 68.4 | 51.8 | 50.0 | 70.0 |
| PCR | 36.8 | 100.0 | 100.0 | 69.2 |
PPV: Positive predictive value, NPV: Negative predictive value, PCR: Polymerase chain reaction, MAT: Microscopic agglutination test, IgM: Immunoglobulin M
Screening and confirmatory models: Variables and scores
| Variable | Correlation coefficient ( | B coefficient | SE | Exp (B) (95% CI) | Score |
|---|---|---|---|---|---|
| Screening model | |||||
| Conjunctival suffusion | 0.057 (0.047)* | 0.15 | 0.17 | 1.16 (0.83-1.62) | 2 |
| Calf tenderness with or without myalgia | 0.093 (0.001)** | 0.78 | 0.24 | 2.19 (1.38-3.50) | 8 |
| Raised serum creatinine | 0.122 (0.000)** | 0.51 | 0.13 | 1.67 (1.30-2.14) | 5 |
| Consider one of the 3 | |||||
| Headache with conjunctival suffusion OR | 0.064 (0.026)* | 0.05 | 0.27 | 1.05 (0.61-1.79) | 1 |
| Headache with jaundice OR | 0.059 (0.041)* | 0.14 | 0.14 | 1.15 (0.88-1.50) | 1 |
| Headache with both conjunctival suffusion and jaundice | 0.076 (0.008)** | 0.39 | 0.38 | 1.47 (0.70-3.08) | 4 |
| Dyspnea or meningism | 0.020 (0.489) | 1 | |||
| Total | 22 | ||||
| Confirmatory model | |||||
| PCR | 0.629 (0.000)** | 12.01 | 1.35 | 164410 (11734-2303452) | 120 |
| IgM ELISA | 0.298 (0.000)** | 2.37 | 0.71 | 10.73 (2.69-42.84) | 20 |
| MAT | 0.594 (0.000)** | 8.84 | 8.84 | 6905.85 (1255.99-37970.62) | 90 |
| Total | 230 |
*Significant at P<0.05, **Significant at P<0.001. SE: Standard error, CI: Confidence interval, OR: Odds ratio, PCR: Polymerase chain reaction, MAT: Microscopic agglutination test, IgM: Immunoglobulin M
Figure 1Receiver operating characteristic curve of different models
Validity of the models with Leptospirosis Burden Epidemiology Reference Group-2 as reference standard in derivation and validation cohorts
| Screening model | Leptospirosis rapid test | Confirmatory model | Added scores of screening, leptospirosis rapid test and confirmatory models | |||||
|---|---|---|---|---|---|---|---|---|
| Derivation cohort | Validation cohort | Derivation cohort | Validation cohort | Derivation cohort | Validation cohort | Derivation cohort | Validation cohort | |
| Sensitivity (%) | 71.18 (67.92-74.22) | 79.16 (65.74-88.27) | 48.16 (44.7-51.65) | 91.66 (80.45-96.71) | 94.18 (92.33-95.61) | 89.58 (77.83-95.47) | 95.20 (93.62-96.59) | 89.58 (77.83-95.47) |
| Specificity (%) | 42.35 (37.74-47.1) | 50.00 (34.07-65.93) | 75.29 (70.98-79.16) | 35.29 (21.49-52.09) | 99.29 (97.95-99.76) | 85.29 (69.87-93.55) | 99.29 (97.95-99.76) | 85.29 (69.87-93.55) |
| PPV (%) | 69.67 (66.42-72.75) | 69.09 (55.97-79.72) | 78.39 (74.52-81.82) | 66.66 (54.66-76.84) | 99.59 (98.83-99.86) | 89.58 (77.83-95.47) | 99.60 (98.84-99.87) | 89.58 (77.83-95.47) |
| NPV (%) | 43.56 (39.38-48.97) | 62.96 (56.34-76.28) | 43.83 (40.28-47.46) | 75.00 (50.5-89.82) | 90.17 (87.14-92.55) | 85.29 (69.87-93.55) | 91.94 (89.09-94.1) | 85.29 (69.87-93.55) |
PPV: Positive predictive value, NPV: Negative predictive value
Figure 2Algorithm for diagnosis of leptospirosis
Net reclassification improvement following the use of algorithm compared to modified Faine’s criteria in validation cohort
| Screening model and rapid test for leptospirosis, compared with parts A+B of modified Faine’s criteria | |||
|---|---|---|---|
| Proportion | Screening model (%) | Rapid test for leptospirosis (%) | Simultaneous use of screening model and rapid test (%) |
| Upǀconfirmed leptospirosis | 33 (68.75) | 37 (77.08) | 39 (81.25) |
| Downǀconfirmed leptospirosis | 2 (4.16) | 0 (0.00) | 0 (0.00) |
| Downǀnonleptospirosis | 5 (14.7) | 2 (5.88) | 0 (0.00) |
| Upǀnonleptospirosis | 12 (35.2) | 14 (41.11) | 0 (0.00) |
| NRI | 43.99 | 41.79 | 81.25 |
| Upǀconfirmed leptospirosis | 0 (0.00) | ||
| Downǀconfirmed leptospirosis | 7 (14.58) | ||
| Downǀnonleptospirosis | 22 (64.71) | ||
| Upǀnonleptospirosis | 1 (2.94) | ||
| NRI | 47.18 | ||
NRI: Net reclassification improvement